{"address1": "Paul-Ehrlich-Strasse 15", "city": "T\u00fcbingen", "zip": "72076", "country": "Germany", "phone": "49 7071 5397 0", "fax": "49 7071 5397 900", "website": "https://www.immatics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in T\u00fcbingen, Germany.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Harpreet  Singh Ph.D.", "age": 49, "title": "CEO, MD, Member of Management Board & Executive Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 901139, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Toni  Weinschenk Ph.D.", "age": 50, "title": "Co-Founder & Chief Innovation Officer", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Arnd  Christ MBA", "age": 58, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steffen  Walter Ph.D.", "age": 47, "title": "Chief Operations Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edward A. Sturchio", "title": "General Counsel & Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Carsten  Reinhardt M.D., Ph.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rainer  Kramer Ph.D.", "age": 59, "title": "Chief Business Officer & Site Head Munich", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Cedrik M. Britten M.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jordan  Silverstein", "age": 44, "title": "Head of Strategy", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans-Georg  Rammensee Ph.D.", "title": "Co-Founder & Member of the Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.0158, "open": 0.0158, "dayLow": 0.0158, "dayHigh": 0.0158, "regularMarketPreviousClose": 0.0158, "regularMarketOpen": 0.0158, "regularMarketDayLow": 0.0158, "regularMarketDayHigh": 0.0158, "beta": 0.827, "volume": 19, "regularMarketVolume": 19, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fiftyTwoWeekLow": 0.0158, "fiftyTwoWeekHigh": 0.0158, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.09765001, "floatShares": 61903070, "bookValue": 4.729, "priceToBook": 0.0033410867, "netIncomeToCommon": 15218000, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.0158, "recommendationKey": "none", "totalCash": 604451968, "totalCashPerShare": 4.973, "ebitda": -29885000, "totalDebt": 16203000, "quickRatio": 8.99, "currentRatio": 9.26, "totalRevenue": 155835008, "debtToEquity": 2.819, "revenuePerShare": 1.474, "returnOnAssets": -0.04002, "returnOnEquity": 0.03841, "grossProfits": 7756000, "freeCashflow": -101741128, "operatingCashflow": -158030000, "revenueGrowth": 2.533, "grossMargins": 0.04977, "ebitdaMargins": -0.19177, "operatingMargins": 0.01605, "financialCurrency": "EUR", "symbol": "IMTXW", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "marketState": "PRE", "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.0158, "shortName": "Immatics N.V.", "longName": "Immatics N.V.", "hasPrePostMarketData": true, "regularMarketChange": 0.0, "regularMarketDayRange": "0.0158 - 0.0158", "fullExchangeName": "NasdaqCM", "fiftyTwoWeekLowChange": 0.0, "fiftyTwoWeekLowChangePercent": 0.0, "fiftyTwoWeekRange": "0.0158 - 0.0158", "fiftyTwoWeekHighChange": 0.0, "fiftyTwoWeekHighChangePercent": 0.0, "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "regularMarketTime": 1743451200, "exchange": "NCM", "messageBoardId": "finmb_8986547", "displayName": "Immatics", "trailingPegRatio": null}